

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Kyogo ITOH et al. Conf.: Unassigned  
Appl. No.: NEW-Rule 53(b) Group: Unassigned  
Div. of 09/763,985  
Filed: February 20, 2004 Examiner: Unassigned  
For: NOVEL TUMOR ANTIGEN PROTEIN SART-3 AND TUMOR  
ANTIGEN PEPTIDES THEREOF

INFORMATION DISCLOSURE STATEMENT  
(SUBMISSION WITH CONTINUATION-IN-PART OR  
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

February 20, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, Applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s).  
09/763,985

U.S. Filing Date(s)  
February 28, 2001

III. FEES


This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
John W. Bailey, #32,881

*JWB*  
JWB/KLR:trb  
0020-5224P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachment(s) : ☒ PTO-1449(s)

☐ References

☐ Foreign Search Report

☐ Other:

(Rev. 02/12/2004)

Form PTO-1449				ATTY DOCKET NO. 0020-5224P		APPLICATION NO. NEW-Rule 53(b) Div. of 09/763,985	
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  (Use several sheets if necessary)				APPLICANT ITOH, Kyogo et al.			
				FILING DATE February 20, 2004		GROUP UNASSIGNED	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	DOCUMENT NUMBER			DATE	NAME	CLASS	SUB CLASS
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUB CLASS
<b>OTHER DOCUMENTS</b> (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	Rosenberg et al., "Treatment of Patients with Metastatic Melanoma with Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2"; <i>J. of the Natl. Cancer Inst.</i> , Vol. 86, No. 15 (August 1994)						
	Rammensee et al., "MHC Ligands and Peptide Motifs: First Listing"; <i>Immunogenetics</i> , Vol. 41., pp.178-228 (1995)						
	Kubo et al., "Definition of Specific Peptide Motifs for Four Major HLA-A Alleles"; <i>J. of Immunology</i> , Vol. 152, pp. 3913-3924 (1994)						
	Kondo et al., "Prominent Roles of Secondary Anchor Residues in Peptide Binding to HLA-A24 Human Class I Molecules"; <i>J. of Immunology</i> , Vol. 155, pp.4307-4312 (1995)						
	Sudo et al., "Differences in MHC Class I Self peptide Repertoires among HLA-A2 Subtypes"; <i>The J. of Immunology</i> , Vol. 155, pp. 4749-4756 (1995)						
	Rivoltini et al., "Induction of Tumor-Reactive CTL from peripheral Blood and Tumor-Infiltrating Lymphocytes of Melanoma Patients by In Vitro Stimulation with an Immunodominant Peptide of the Human Melanoma Antigen MART-1"; <i>The J. of Immunology</i> , Vol. 154, pp. 2257-2265 (1995)						
	Kharkevitch et al., "Characterization of Autologous Tumor-Specific T-Helper 2 Cells in Tumor-Infiltrating Lymphocytes from a Patient with Metastatic Melanoma"; <i>Int. J. Cancer</i> , Vol. 58, pp.317-323 (1994)						
	Van Tsai et al., "Identification of Subdominant CTL Epitopes of the GP100 Melanoma-Associated Tumor Antigen by Primary In Vitro Immunization with Peptide-Pulsed Dendritic Cells"; <i>The J. of Immunology</i> , Vol. 158, pp. 1796-1802 (1997)						
	Altman et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes"; <i>Science</i> , Vol. 274, pp.94-96 (Oct. 1996)						
	Nakao et al., "HLA A2601-restricted CTLs Recognize a peptide Antigen Expressed on Squamous Cell Carcinoma"; <i>Cancer Research</i> , Vol. 55, pp. 4248-4252 (Oct. 1995)						
	Thomsen et al., "DELIVERY OF MULTIPLE CD8 Cytotoxic T Cell Epitopes by DNA Vaccination"; <i>The J. of Immunology</i> , Vol. 160, pp. 1717-1723 (1998)						
	KIAA0156 (Genbank Accession No. D63879), (July 10, 1997)						
	HLA-A2 cDNA (Genbank Accession No. M84379), (January 7, 1995)						
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.B.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449		ATTY DOCKET NO. 0020-5224P		APPLICATION NO. NEW-Rule 53(b) Div. of 09/763,985		
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  (Use several sheets if necessary)		APPLICANT ITO et al.				
		FILING DATE February 20, 2004		GROUP Unassigned		
<b>U.S. PATENT DOCUMENTS</b>						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	5,750,395	May 1998	Fikes et al.			
<b>FOREIGN PATENT DOCUMENTS</b>						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION
						YES NO
	WO 00/55174	2000-09-21	PCT			
	EP 1 033 401 A2	2000-09-06	EPO			
<b>OTHER DOCUMENTS</b> (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)						
	TOH et al., Cellular Immunology, Vol. 177, Article No. CI971105, pp. 137-143, (1997).					
	YANG et al., CANCER RESEARCH, Vol. 59, pp. 4056-4063, (1999).					
	Accession No. HSORF51, "Human mRNA for KIA0156 gene, complete cds.", August 8, 1995, EMBL Database.					
	Accession No. AAG01853, "Human Secreted protein, SEQ ID NO: 5934.", September 6, 2000, EMBL Database.					
	Shichijo et al., "A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T lymphocytes" J. Exp. Med, Vol. 187, No. 3, pp. 277-288, (February 2, 1998)					
	Gohara "Histocompatibility Leukocyte Antigen-A2402-restricted Cytotoxic T Lymphocytes Recognizing Adenocarcinoma in Tumor-infiltrating Lymphocytes of Patients with Colon Cancer" Jpn. J. Cancer Res., Vol. 88, No. 2, pp. 198-204, (February 1997)					
	Nagase "Prediction of the Coding sequences of Unidentified Human Genes. IV. The Coding Sequence of 40 New Genes (KIAA0121-KIAA0160) Deduced by Analysis of cDNA Clones from Human Cell Line KG-1" J. Clin. Invest., Vol. 2, No. 4, pp. 167-174 (August 1995)					
	Yotnda "Cytotoxic T cell Response Against the Chimeric ETV6-AML1 Protein in Childhood Acute Lymphoblastic Leukemia" J. Clin. Invest., Vol. 102, No. 2, pp. 455-462, (July 1998)					
	Takahashi "Recognition of gp43 Tumor-Associated Antigen Peptide by both HLA-A2 Restricted CTL Lines and Antibodies from Melanoma Patients" Cellular Immunology, Vol. 178, No. 2, pp. 162-171, (June 15, 1997)					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

Form PTO-1449			ATTY DOCKET NO. 0020-5224P		APPLICATION NO. NEW-Rule 53(b) Div. of 09/763,985	
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  (Use several sheets if necessary)			APPLICANT ITOH et al.			
			FILING DATE February 20, 2004		GROUP Unassigned	
<b>U.S. PATENT DOCUMENTS</b>						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
<b>OTHER DOCUMENTS</b> (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	Crystal, R.G. Science, Vol. 270, pp. 404-410, (October 1995)					
	Tait et al., Clin. Canc. Res., Vol. 5, pp. 1708-1714, (July 1999)					
	Gura, Science, Vol. 278, pp. 1041-1042, (1997)					
	Miyagi et al., Clinical Cancer Res., Vo. 7, pp.3950-3962, (2001)					
	Kurshid et al., Analytical Biochemistry, Vol. 208, pp. 138, (1993) Abstract					
	Gaiger et al., Blood, Vol. 96, pp. 1480-1489, (2000)					
	Boon, Adv. Can. Res., Vo. 58, pp. 177-210, (1992)					
	Spitler, Cancer Biotherapy, Vol. 10, pp. 1-3, (1995)					
	Ezzel, J. NIH Res., Vol. 7, pp. 46-49, (1995)					
	Nagase et al., DNA Res., Vol. 2, pp. 167-174, supplement 199-210, (1995)					
	Campbell, Monoclonal antibody technology, Elsevier Science Publishers, Chapter 1, pages 1-32					
	Sambrook et al., Molecular Cloning, A Laboratory Manual, Chapters 3 and 12 (1989)					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						